<DOC>
	<DOCNO>NCT00636740</DOCNO>
	<brief_summary>The objective MER-101-03 examine effect two different dose regimen MER-101 20mg tablet versus Zometa 4mg IV infusion once-monthly therapy . The effect monitor weekly basis measure various marker bone metabolism . Patients enrol receive previous bisphosphonate therapy . The study carry prostate cancer patient longer hormone therapy . Treatment study 2-month period .</brief_summary>
	<brief_title>Multi-Center Phase II Study Compare MER-101 20mg Tablets Intravenous Zometa 4mg Male Bisphosphonate-Naive , Hormone Refractory Prostate Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Prostate Cancer rise PSA level hormone treatment bone metastasis base Xray . Already bisphosphonate treatment ( Zometa , Fosamax , Actonel )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Prostate cancer , hormone resistant , bisphosphonate</keyword>
</DOC>